Table 6. Study results.
NR: no results
| Author | Intervention or matching placebo | Mean weight change (%) | Mean waist circumference (cm) | Percentage of patients with weight loss above: | |||
| 5% | 10% | 15% | 20% | ||||
| Garvey et al. [12] | Semaglutide 2.4 mg | -14.8 | -15.2 | 77.1 | 61.8 | 52.1 | 36.1 |
| Placebo | -2.4 | -4.3 | 34.4 | 13.3 | 7.0 | 2.3 | |
| Kadowaki et al. [13] | Semaglutide 1.7 mg | -9.6 | -7.8 | 72.4 | 41.8 | 24.5 | 11.2 |
| Semaglutide 2.4 mg | -13.2 | -11.2 | 82.9 | 60.6 | 40.9 | 19.7 | |
| Placebo | NR | NR | NR | ||||
| Knop et al. [14] | Semaglutide 50 mg | -15.1 | NR | 85 | 69 | 54 | 34 |
| Placebo | -2.4 | NR | 26 | 12 | 6 | 3 | |
| Kosiborod et al. [15] | Semaglutide 2.4 mg | -13.3 | -11.7 | NR | 65.9 | 43.9 | 23.6 |
| Placebo | -2.6 | -2.7 | NR | 9.5 | 2.1 | 0.4 | |
| Mu et al. [16] | Semaglutide (initiated at 0.25mg and increased every four weeks until the target dose of 2.4 mg) | -12.1 | -10.7 | 85 | 63 | 34 | 14 |
| Placebo | -3.6 | -3.9 | 31 | 10 | 6 | 2 | |
| Rubino et al. [17] | Semaglutide 2.4 mg (68 weeks) | -7.1 | -6.4 | 88.7 | 79.0 | 63.7 | 39.6 |
| Semaglutide 2.4 mg (20 weeks) followed by placebo (48 weeks) | +6.1 | +3.3 | 47.6 | 20.4 | 9.2 | 4.8 | |
| Rubino et al. [18] | Semaglutide 2.4 mg | -15.8 | -13.2 | NR | 70.9 | 55.6 | 38.5 |
| Liraglutide 3.0 mg | -6.4 | -6.6 | NR | 25.6 | 12.0 | 6.0 | |
| Placebo | NR | NR | NR | ||||
| Wadden et al. [19] | Semaglutide 2.4 mg | -16.0 | -14.6 | 86.6 | 75.3 | 55.8 | 35.7 |
| Placebo | -2.4 | -4.3 | 47.6 | 27 | 13.2 | 3.7 | |
| Wilding et al. [20] | Semaglutide 2.4 mg | -14.9 | -13.54 | 86.4 | 69.1 | 50.5 | NR |
| Placebo | -2.4 | -4.13 | 31.5 | 12.0 | 4.9 | NR | |
| Ghusn et al. [21] | Semaglutide 1.7 mg or 2.4 mg | -10.9 | NR | 87.3 | 54.9 | 23.5 | 7.8 |